Biogen 232SM303

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

This study will evaluate HD nusinersen in participants previously treated with risdiplam who may not be receiving the optimal benefit from treatment because they have reached the dose ceiling of 5 mg.This Phase 3b, open-label, single-arm, interventional study will evaluate the efficacy and safety of HD nusinersen in nonambulatory participants with later-onset SMA (symptom onset at age 6 months) who received treatment with risdiplam in the clinical practice setting.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 03 Sep 2024. Study ID: 850465

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).